Project Grant R01AI188789
Award Date
11/14/24
Completion Date
10/31/29
Dollars Obligated
$832K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to define the immunogenic landscape of early mosquito-stage Plasmodium falciparum parasites in order to accelerate the discovery of malaria transmission-blocking vaccines. The $3,762,999 award, effective July 5, 2024 through May 31, 2029, will support comprehensive proteomic analysis of P. falciparum gametes,...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $738,445 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Drexel University in Philadelphia, PA. The grant is for a 5-year period from August 1, 2024 to July 31, 2029. The purpose of this grant is to develop an mRNA-based multivalent malaria vaccine that can concurrently drive durable antibody-mediated and cell-mediated protective immune responses against both pre-erythrocytic...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $310,492 to the University of Washington to conduct research aimed at understanding and overcoming immune evasion mechanisms used by Plasmodium parasites that cause malaria. The key objectives are to characterize the memory B cell responses specific to the circumsporozoite protein (CSP) during Plasmodium...
The federal Project Grant award R01AI183533, totaling $813,160.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite, specifically Plasmodium falciparum and Plasmodium vivax. The key objectives are to evaluate the protective efficacy of vaccine antigens targeting...
This federal Project Grant award of $1,770,366.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research focused on enhancing T and B cell responses to Plasmodium infection and vaccination via IL-15 therapy. The project aims to define the mechanistic pathways by which IL-15 therapy promotes the differentiation of T follicular helper cells and germinal center...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $699,814 to Florida International University (FIU) to study molecular mechanisms of malaria parasite-mosquito midgut interactions and develop new transmission-blocking vaccine approaches. The key objectives are to functionally characterize mosquito and malaria parasite proteins that mediate the parasite...
This federal Project Grant award from the National Institutes of Health (NIH) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $205,125 to the Hennepin Healthcare Research Institute (HHRI) to investigate the impact of microbial exposure on the efficacy of Plasmodium (malaria) vaccines. The key objectives are to: 1) define the immune response to Plasmodium vaccination in a mouse model with diverse microbial exposure, and 2) test whether the IL-15 adjuvant can...
This $2,960,775 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate how prior exposure to malaria compromises the effectiveness of radiation-attenuated sporozoite (RAS) vaccines. The goal is to gain mechanistic insights into how hemozoin, a byproduct of malaria infection, disrupts the priming of CD8 T cell responses and liver-stage immunity induced by...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,116 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU) to develop novel 4-aminoquinoline compounds as potential therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The project aims to further develop a lead compound, MH02-060, which has demonstrated enhanced metabolic stability and in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $147,656 to support research aimed at understanding the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The research will integrate biochemical and microscopy approaches to decipher the location and function of these transmembrane proteins within the parasite's...